Table 1. Dup15q syndrome participant characteristics.
Older participants tested in Orlando did not undergo cognitive testing, as age-appropriate cognitive tests were not available. N/A = not available.
| Group | Age (months) | Site | Gender | Meds | Genetics | Epilepsy | Verbal developmental quotient (VDQ) | Nonverbal developmental quotient (NVDQ) |
|---|---|---|---|---|---|---|---|---|
| Dup15q | 99.9 | UCLA | Female | risperidone | isodicentric | no | 43 | 47 |
| Dup15q | 42.5 | UCLA | Male | none | isodicentric | no | 12 | 32 |
| Dup15q | 44.5 | UCLA | Male | none | isodicentric | no | 72 | 64 |
| Dup15q | 28.1 | UCLA | Female | none | isodicentric | no | 39 | 46 |
| Dup15q | 42.8 | UCLA | Female | levetiracetam | isodicentric | yes | 6 | 4 |
| Dup15q | 55.9 | UCLA | Female | none | interstitial | no | 105 | 100 |
| Dup15q | 230.1 | UCLA | Female | zoloft | interstitial | no | N/A | 56 |
| Dup15q | 54.2 | UCLA | Male | none | interstitial | no | 8 | 24 |
| Dup15q | 57 | UCLA | Male | none | isodicentric | no | 48 | 46 |
| Dup15q | 143.8 | UCLA | Female | levetiracetam | isodicentric | yes | 7 | 12 |
| Dup15q | 106.1 | UCLA | Male | no anticonvulsant | interstitial | no | 33 | 34 |
| Dup15q | 15.8 | UCLA | Female | no anticonvulsant | isodicentric | no | 48 | 79 |
| ASD | 61.2 | UCLA | Male | Focalin, risperdone | N/A | no | 51 | 48 |
| ASD | 26.6 | UCLA | Male | none | N/A | no | 19 | 45 |
| ASD | 39.3 | UCLA | Male | none | N/A | no | 33 | 46 |
| ASD | 63 | UCLA | Male | none | N/A | no | 43 | 41 |
| ASD | 28.8 | UCLA | Male | none | N/A | no | 28 | 52 |
| ASD | 53.2 | UCLA | Female | risperidone | N/A | no | 56 | 51 |
| ASD | 48.6 | UCLA | Male | none | N/A | no | 17 | 49 |
| ASD | 32.3 | UCLA | Male | none | N/A | no | 25 | 43 |
| ASD | 58.5 | UCLA | Female | zoloft | N/A | no | 103 | 74 |
| ASD | 98.7 | UCLA | Male | melatonin | N/A | no | 21 | 50 |
| TD | 57 | UCLA | Female | none | N/A | no | 122 | 94 |
| TD | 54 | UCLA | Male | none | N/A | no | 98 | 97 |
| TD | 29 | UCLA | Male | none | N/A | no | 131 | 157 |
| TD | 55 | UCLA | Male | none | N/A | no | 140 | 107 |
| TD | 38.8 | UCLA | Female | none | N/A | no | 145 | 149 |
| TD | 43.8 | UCLA | Male | none | N/A | no | 109 | 115 |
| TD | 40.8 | UCLA | Male | none | N/A | no | 141 | 113 |
| TD | 59.6 | UCLA | Female | none | N/A | no | 127 | 103 |
| TD | 59.6 | UCLA | Male | none | N/A | no | 112 | 117 |
| Dup15q | 93.2 | Orlando | Male | rufinamide 1200 mg b.i.d., levetiracetam 2000 mg b.i.d., lacosamide 40 mg b.i.d., Epidiolex (canibidiol) 7 mL x2 | isodicentric | yes | 39 | 37 |
| Dup15q | 108.2 | Orlando | Male | no anticonvulsant | interstitial | no | N/A | N/A |
| Dup15q | 147.3 | Orlando | Female | lamotrigine 300 mg b.i.d. lacosamide 100mg b.i.d. felbamate 1200mg/800mg/1000mg | isodicentric | yes | 14 | N/A |
| Dup15q | 110.5 | Orlando | Male | no anticonvulsant | isodicentric | no | 12 | 21 |
| Dup15q | 117.5 | Orlando | Female | no anticonvulsant | interstitial | no | 37 | 44 |
| Dup15q | 65.45 | Orlando | Male | levetiracetam 500mg AM 750mg PM lamotrigine 100 mg b.i.d. | isodicentric | yes | 9 | 13 |
| Dup15q | 44.9 | Orlando | Female | no anticonvulsant | interstitial | no | 11 | 27 |
| Dup15q | 47 | Orlando | Female | no anticonvulsant | isodicentric | no | N/A | N/A |
| Dup15q | 81.2 | Orlando | Male | valproic acid 250mg b.i.d. oxcarbazepine 300mg b.i.d. | isodicentric | yes | N/A | N/A |
| Dup15q | 48.7 | Orlando | Male | no anticonvulsant | isodicentric | no | N/A | N/A |
| Dup15q | 384 | Orlando | Female | valproic acid | interstitial | yes | N/A | N/A |
| Dup15q | 161.6 | Orlando | Male | no anticonvulsant | interstitial | no | N/A | N/A |
| Dup15q | 29.4 | Orlando | Male | no anticonvulsant | isodicentric | no | 36 | 29 |
| Dup15q | 111.7 | Orlando | Female | no anticonvulsant | interstitial | no | 26 | 24 |
| Dup15q | 86 | Orlando | Female | no anticonvulsant | isodicentric | no | N/A | N/A |